153 related articles for article (PubMed ID: 11997409)
1. Lipid lowering in patients with diabetes mellitus: what coronary heart disease risk threshold should be used?
Rowland Yeo K; Yeo WW
Heart; 2002 May; 87(5):423-7. PubMed ID: 11997409
[TBL] [Abstract][Full Text] [Related]
2. Lipid-lowering for prevention of coronary heart disease: what policy now?
Ul Haq I; Ramsay LE; Pickin DM; Yeo WW; Jackson PR; Payne JN
Clin Sci (Lond); 1996 Oct; 91(4):399-413. PubMed ID: 8983865
[TBL] [Abstract][Full Text] [Related]
3. Coronary heart disease prevention in clinical practice: are patients with diabetes special? Evidence from two studies of older men and women.
Emberson JR; Whincup PH; Lawlor DA; Montaner D; Ebrahim S
Heart; 2005 Apr; 91(4):451-5. PubMed ID: 15772196
[TBL] [Abstract][Full Text] [Related]
4. Population implications of lipid lowering for prevention of coronary heart disease: data from the 1995 Scottish health survey.
Haq IU; Ramsay LE; Wallis EJ; Isles CG; Ritchie LD; Jackson PR
Heart; 2001 Sep; 86(3):289-95. PubMed ID: 11514481
[TBL] [Abstract][Full Text] [Related]
5. Coronary heart disease risk assessment in diabetes mellitus: comparison of UKPDS risk engine with Framingham risk assessment function and its clinical implications.
Song SH; Brown PM
Diabet Med; 2004 Mar; 21(3):238-45. PubMed ID: 15008833
[TBL] [Abstract][Full Text] [Related]
6. Use of statins in the secondary prevention of coronary heart disease: is treatment equitable?
Reid FD; Cook DG; Whincup PH
Heart; 2002 Jul; 88(1):15-9. PubMed ID: 12067933
[TBL] [Abstract][Full Text] [Related]
7. Coronary heart disease prevention and age inequalities: the first year of the National Service Framework for CHD.
Hippisley-Cox J; Pringle M; Cater R; Coupland C; Meal A
Br J Gen Pract; 2005 May; 55(514):369-75. PubMed ID: 15904556
[TBL] [Abstract][Full Text] [Related]
8. Reproducibility of individualized coronary heart disease risk calculations in patients with diabetes mellitus.
Lambert AP; Hunt MA; Day AP; Bayly GR; Dayan CM
Diabet Med; 2002 Jun; 19(6):514-7. PubMed ID: 12060065
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials.
Costa J; Borges M; David C; Vaz Carneiro A
BMJ; 2006 May; 332(7550):1115-24. PubMed ID: 16585050
[TBL] [Abstract][Full Text] [Related]
10. Heart protection study: LDL lowering therapy and cardiovascular outcomes in patients with low cholesterol levels or diabetes.
Kulkarni M; Reaven PD
Curr Diab Rep; 2002 Jun; 2(3):269-73. PubMed ID: 12643184
[No Abstract] [Full Text] [Related]
11. Laboratory-based calculation of coronary heart disease risk in a hospital diabetic clinic.
Bayly GR; Bartlett WA; Davies PH; Husband D; Haddon A; Game FL; Jones AF
Diabet Med; 1999 Aug; 16(8):697-701. PubMed ID: 10477217
[TBL] [Abstract][Full Text] [Related]
12. Prescription of lipid-lowering medications for patients with type 2 diabetes mellitus and risk-associated LDL cholesterol: a nationwide study of guideline adherence from the Swedish National Diabetes Register.
Karlsson SA; Franzén S; Svensson AM; Miftaraj M; Eliasson B; Andersson Sundell K
BMC Health Serv Res; 2018 Nov; 18(1):900. PubMed ID: 30486824
[TBL] [Abstract][Full Text] [Related]
13. Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey.
Primatesta P; Poulter NR
BMJ; 2000 Nov; 321(7272):1322-5. PubMed ID: 11090516
[TBL] [Abstract][Full Text] [Related]
14. A prospective study in primary care in patients without vascular disease comparing levels of coronary risk factors in those recommended for lipid-lowering drugs based on either absolute risk or absolute risk reduction.
Ramachandran S; Croft P; Neary RH
Prev Cardiol; 2003; 6(1):17-21. PubMed ID: 12624557
[TBL] [Abstract][Full Text] [Related]
15. Management of dyslipidemia in adults with diabetes.
Haffner SM
Diabetes Care; 1998 Jan; 21(1):160-78. PubMed ID: 9538988
[TBL] [Abstract][Full Text] [Related]
16. Diabetes and coronary heart disease: the role of hyperlipidemia.
Betteridge DJ
J Diabet Complications; 1990; 4(2):53-6. PubMed ID: 2145299
[No Abstract] [Full Text] [Related]
17. Lipid lowering and coronary heart disease risk: how appropriate are the national guidelines?
Forge BH; Briganti EM
Med J Aust; 2001 Nov; 175(9):471-5. PubMed ID: 11758075
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study.
Elkeles RS; Diamond JR; Poulter C; Dhanjil S; Nicolaides AN; Mahmood S; Richmond W; Mather H; Sharp P; Feher MD
Diabetes Care; 1998 Apr; 21(4):641-8. PubMed ID: 9571357
[TBL] [Abstract][Full Text] [Related]
19. Adherence to National Cholesterol Education Program Treatment goals in postmenopausal women with heart disease. The Heart and Estrogen/Progestin Replacement Study (HERS). The HERS Research Group.
Schrott HG; Bittner V; Vittinghoff E; Herrington DM; Hulley S
JAMA; 1997 Apr 23-30; 277(16):1281-6. PubMed ID: 9109465
[TBL] [Abstract][Full Text] [Related]
20. Systematic review of lipid lowering for primary prevention of coronary heart disease in diabetes.
Gami AS; Montori VM; Erwin PJ; Khan MA; Smith SA;
BMJ; 2003 Mar; 326(7388):528-9. PubMed ID: 12623912
[No Abstract] [Full Text] [Related]
[Next] [New Search]
